CMV-Specific T Cells for prevention of CMV Reactivation After Allogeneic Stem Cell Transplantation.

The Use of Donor-Derived allogeneic CMV-Specific Cytotoxic T Cells for prevention of CMV Reactivation After Allogeneic Stem Cell Transplantation.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140818018842N30

Enrollment

Registered

2023-02-18

Start date

2023-02-20

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allogeneic stem cells transplantation. Stem cells transplant status

Interventions

Intervention 1: Patients in the intervention arm will receive the systemic intravenous infusion of 10 million cells/m2 CMV Specific T-cells after day 14 post-transplants. infusion of CMV-specific T-

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Allogeneic stem cell transplantation recipient Age >=?? CMV seropositive donor

Exclusion criteria

Exclusion criteria: Unrelated donor Participation in other clinical trials

Design outcomes

Primary

Measure	Time frame
Number of Patients With Grades 3-5 of cytotoxic T-cell infusion-related Adverse Events (Version 4.03). Timepoint: Daily during the seven days after the injection. Method of measurement: Physical exam, history and lab tests.;Cytomegalovirus reactivation. Timepoint: Weekly intervals until three months after the T-cell injection. Method of measurement: RT-PCR in the peripheral blood to assess Cytomegalovirus-DNA.	—

Measure

Time frame

Number of Patients With Grades 3-5 of cytotoxic T-cell infusion-related Adverse Events (Version 4.03). Timepoint: Daily during the seven days after the injection. Method of measurement: Physical exam, history and lab tests.;Cytomegalovirus reactivation. Timepoint: Weekly intervals until three months after the T-cell injection. Method of measurement: RT-PCR in the peripheral blood to assess Cytomegalovirus-DNA.

—

Secondary

Measure	Time frame
Prolonged cytopenia. Timepoint: Daily during the first seven days after the injection and then weekly until one-month after the injection. Method of measurement: Complete peripheral blood cell count.;Acute Graft versus Host Disease. Timepoint: Weekly interval until 100 days post-transplantation. Method of measurement: physical exam, lab test, and biopsy.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamad Ahmadvand

Tehran University of Medical Sciences

ahmadvand.mohamad64@yahoo.com+98 21 8800 4140

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026